Safety, effectiveness, and subjective experience with topical bimatoprost 0.03% for eyelash growth

Dermatol Surg. 2010 May;36(5):638-49. doi: 10.1111/j.1524-4725.2010.01519.x. Epub 2010 Apr 1.


Background: Ocularly applied bimatoprost 0.03% is associated with increased eyelash growth.

Objective: To assess the safety, efficacy, and subjective experience of using dermal application of bimatoprost 0.03% for the growth of natural eyelashes.

Methods: Prospective, open-label study of subjects who desired longer, thicker (fuller), and darker natural eyelashes. Bimatoprost was applied to the upper lid margin once daily for 12 weeks. Adverse events and intraocular pressure were assessed, and subjects completed health outcomes questionnaires. Eyelash growth and darkening were scored using photographs taken at weeks 1 and 12.

Results: All subjects were female (N=28). No serious or unexpected adverse events were reported. The mean change from baseline intraocular pressure was less than 1 mmHg at each time point, but was statistically significant at weeks 1 and 4 (p< or =.047). At week 12, all subjects had noticed significant growth or darkening. Post hoc analysis of photographs corroborated these reports (p<.001).

Conclusion: Bimatoprost was found safe for eyelid application and was associated with enhanced eyelash growth. All subjects noticed favorable changes in the appearance of their eyelashes.

Publication types

  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Topical
  • Adult
  • Aged
  • Amides / administration & dosage*
  • Antihypertensive Agents / administration & dosage
  • Bimatoprost
  • Cloprostenol / administration & dosage
  • Cloprostenol / analogs & derivatives*
  • Eyelashes / drug effects
  • Eyelashes / growth & development*
  • Female
  • Follow-Up Studies
  • Humans
  • Intraocular Pressure / drug effects
  • Male
  • Middle Aged
  • Prospective Studies
  • Surveys and Questionnaires
  • Treatment Outcome


  • Amides
  • Antihypertensive Agents
  • Cloprostenol
  • Bimatoprost